Literature DB >> 36261506

Large Bore Portal Vein Thrombectomy: An Inari FlowTriever Case Series.

Ian W Sullivan1, Adam Fonseca2, McKenzie Brown3, Joseph Ness3, Marc Borge2, Parag Amin4, Christopher Molvar2.   

Abstract

PURPOSE: Portal vein thrombus (PVT) can worsen portal hypertension and hepatic decompensation in patients with cirrhosis and impact liver transplant outcomes. This retrospective case series describes large bore mechanical thrombectomy of PVT with the Inari FlowTriever device during, or remotely after, transjugular intrahepatic portosystemic shunt (TIPS) placement.
MATERIALS AND METHODS: Ten patients with PVT were treated with large bore thrombectomy. All patients had underlying cirrhosis, complicated by portal hypertension with acute/subacute PVT. Thrombectomy was performed either with TIPS placement, or via a previously placed thrombosed shunt. Median time from TIPS placement to thrombectomy was 3 years.
RESULTS: Thrombectomy was technically successful in all patients with a majority achieving complete resolution of PVT in a single session. During mean follow-up of 13.3 months, all patients achieved complete resolution of PVT without recurrence.
CONCLUSION: Large bore mechanical thrombectomy together with TIPS is a feasible and effective treatment of acute/subacute PVT in cirrhotic patients with portal hypertension, often with complete resolution in a single session.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).

Entities:  

Keywords:  Portal vein; Thrombectomy; Thrombosis; Transjugular intrahepatic portosystemic shunt (TIPS)

Year:  2022        PMID: 36261506     DOI: 10.1007/s00270-022-03286-w

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.797


  7 in total

Review 1.  Portal vein thrombosis, revisited.

Authors:  Massimo Primignani
Journal:  Dig Liver Dis       Date:  2009-09-18       Impact factor: 4.088

Review 2.  Acute Portal Vein Thrombosis: Current Trends in Medical and Endovascular Management.

Authors:  Stephen M Seedial; Samdeep K Mouli; Kush R Desai
Journal:  Semin Intervent Radiol       Date:  2018-08-06       Impact factor: 1.513

3.  Risk factors for thrombophilia in extrahepatic portal vein obstruction.

Authors:  Massimo Primignani; Ida Martinelli; Paolo Bucciarelli; Tullia Battaglioli; Raffaella Reati; Federica Fabris; Alessandra Dell'era; Emanuela Pappalardo; Pier Mannuccio Mannucci
Journal:  Hepatology       Date:  2005-03       Impact factor: 17.425

4.  Transjugular intrahepatic portosystemic shunt (TIPS) in the treatment of venous symptomatic chronic portal thrombosis in non-cirrhotic patients.

Authors:  José I Bilbao; Mariana Elorz; Isabel Vivas; Antonio Martínez-Cuesta; Gorka Bastarrika; Alberto Benito
Journal:  Cardiovasc Intervent Radiol       Date:  2004-08-12       Impact factor: 2.740

Review 5.  Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases.

Authors:  Patrick G Northup; Juan Carlos Garcia-Pagan; Guadalupe Garcia-Tsao; Nicolas M Intagliata; Riccardo A Superina; Lara N Roberts; Ton Lisman; Dominique C Valla
Journal:  Hepatology       Date:  2021-01-20       Impact factor: 17.425

Review 6.  Thrombolysis and Transjugular Intrahepatic Portosystemic Shunt Creation for Acute and Subacute Portal Vein Thrombosis.

Authors:  Murthy R Chamarthy; Matthew E Anderson; Anil K Pillai; Sanjeeva P Kalva
Journal:  Tech Vasc Interv Radiol       Date:  2016-02-01

7.  Pretransplantation Portal Vein Recanalization and Transjugular Intrahepatic Portosystemic Shunt Creation for Chronic Portal Vein Thrombosis: Final Analysis of a 61-Patient Cohort.

Authors:  Bartley Thornburg; Kush Desai; Ryan Hickey; Elias Hohlastos; Laura Kulik; Daniel Ganger; Talia Baker; Michael Abecassis; Juan C Caicedo; Daniela Ladner; Jonathan Fryer; Ahsun Riaz; Robert J Lewandowski; Riad Salem
Journal:  J Vasc Interv Radiol       Date:  2017-10-17       Impact factor: 3.464

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.